Skip to main content

Table 1 Demographics and methods of included clinical trials

From: Is local platelet-rich plasma injection clinically superior to hyaluronic acid for treatment of knee osteoarthritis? A systematic review of randomized controlled trials

  Cerza et al., 2012 [22] Filardo et al., 2012 [11] Sanchez et al., 2012 [24] Vaquerizo et al., 2013 [25] Filardo et al., 2015 [23] Raeissadat et al., 2015 [13] Montañez-Heredia, et al. 2016 [14]
Registered Not recorded Not recorded Real Decreto
223/2004
Real Decreto
223/2004
ClinicalTrials.gov, NCT01670578 IRCT20140121134
42N5
ClinicalTrials.gov, NCT02448407
Subject enrollment date September 2009–September 2010 Not recorded January 2008–November 2009 Not recorded 2009–2013 Not recorded January to March 2014
Country Italy Italy Spain Spain Italy Iran Spain
Conflict of interest None None None Not mentioned Not mentioned None None
No. of subjects (knees) 120 (120) 109 (109) 176 (176) 96 (96) 183 (183) 160 (160) 55 (55)
Sex: male, female 53, 67 68, 41 85, 91 38, 58 112, 71 23, 116 21, 32
Mean age, yr 66.4 56.5 59.8 63.6 55.34 58.79 63.9
BMI, kg/m2 Not recorded 26.5 28.0 30.9 25.7 27.68 29.7
Bilateral vs. unilateral knee injections Unilateral Unilateral Unilateral Unilateral Unilateral Unilateral Unilateral
Ultrasound-guided injections or not Not mentioned Not mentioned Not mentioned Not mentioned Not mentioned Not mentioned No
Study group 1 60 Patients 54 Patients 87 Patients 48 Patients 96 Patients 87 Patients 28 Patients
Study group 2 60 Patients 55 Patients 89 Patients 48 Patients 96 Patients 73 Patients 27 Patients
Baseline characteristic differences between groups No differences No differences No differences No differences No differences except for age No differences except for age, sex, WOMAC (pain, function) No differences
Radiographic classification Kellgren-Lawrence Kellgren-Lawrence Ahlbäck Kellgren-Lawrence Kellgren-Lawrence Kellgren-Lawrence Kellgren-Lawrence
  Grade I: 25 Average of grade Grade I: 87 Grade II: 32 Average of grade Grade I: 6 Grade I: 7
Grade II: 22 2.2 for PRP group and 2.1 for HA group Grade II: 64 Grade III: 47 2.0 for PRP group and 2.0 for HA group Grade II: 91 Grade II: 19
Grade III: 13   Grade III: 23 Grade IV: 17   Grade III: 75 Grade III: 27
      Grade IV: 28  
Length of follow-up 24 Weeks 12 Months 6 Months 48 Weeks 12 Months 52 Weeks 6 Months
Outcome scores used WOMAC IKDC, Tegner, KOOS, EQ VAS WOMAC, VAS WOMAC, Lequesne, OMERACT-OARSI IKDC, KOOS, EQ VAS, Tegner score WOMAC, SF-36 VAS, KOOS, EuroQol
Prior surgeries No 63 Subjects None in last year Not recorded 101 Subjects Not recorded No
Prior injections No Not recorded None in prior 6 months None in prior 6 months Conservative None in prior 2 weeks No
PRP no. of injections 4 3 3 3 3 2 3
PRP volume per Injection 5.5 ml 8 ml 12 ml 8 ml 5 ml 4–6 ml 5 ml
Injection interval, wk 1 1 1 2 1 4 2
Injection approach Superolateral Not recorded Superolateral Superolateral Not recorded Anteromedial or lateral midpatellar Not recorded
Primary and secondary outcomes WOMAC score before infiltration and at 4, 12, and 24 weeks after first injection IKDC, EQ VAS, Tegner, and KOOS scores, range of motion and knee circumference changes were evaluated at 2, 6, and 12 months WOMAC scores at 1, 2, and 6 months WOMAC and Lequesne scores at 24 and 48 weeks IKDC, KOOS, EQ VAS, and Tegner scores at baseline and then at 2, 6, and 12 months after last injection WOMAC and SF-36 scores at 52 weeks VAS, KOOS, EuroQol following the third infiltration and after 3 and 6 months following final infiltration
  1. Abbreviations: EQ VAS EuroQol visual analogue scale, IKDC International Knee Documentation Committee, KOOS Knee Injury and Osteoarthritis Outcome Score, OMERACT-OARSI Outcome Measures in Rheumatology Osteoarthritis Research Society International, PRP Platelet-rich plasma, SF-36 36-Item Short Form Health Survey, VAS Visual analogue scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index